Use of the Protease Inhibitor Saquinavir Hard Gel in Human Immunodeficiency Virus-infected Patients in the Early Period of Highly Active Antiretroviral Therapy: Does it Affect Long-term Treatment Outcome?
Authors:
- Søren Jensen-FangelSJSøren Jensen-Fangel
- Court PedersenCPCourt Pedersen
- Henrik NielsenHNHenrik Nielsen
- Palle TaurisPTPalle Tauris
- Axel MøllerAMAxel Møller
- Henrik Toft SørensenHSHenrik Toft Sørensen
- Niels ObelNONiels Obel
- 1 October 2003
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 35 (10) , 743-749
Abstract
Saquinavir hard gel capsule (hgc), the first human immunodeficiency virus (HIV) protease inhibitor (PI) used in clinical practice, has been shown to have insufficient effectiveness. A population-based cohort study assessed the long-term consequences of using saquinavir hgc as initial PI in HIV-infected patients pre-exposed to nucleoside reverse transcriptase inhibitors. 121 patients starting a regimen with saquinavir hgc were compared with 91 starting with non-boosted indinavir (n = 72) or ritonavir (n = 19). Median follow-up time was 4.6 and 4.7 y for the 2 groups. Starting with saquinavir hgc was associated with a lower overall probability of achieving an undetectable viral load [risk ratio (RR) = 0.41, 95%, confidence interval (95% CI) 0.30-0.56]. However, the lower probability of having undetectable viral load during follow-up declined over time with odds ratios (OR) = 0.27 (95%, CI 0.14-0.54), 0.35 (951% CI 0.19-0.66), 0.47 (95% CI 0.24-0.91) and 0.73 (95% CI 0.34-1.55) at 60, 120, 180 and 240 weeks, respectively, after starting HAART. Starting with saquinavir hgc was correlated with a higher risk of having the initial PI discontinued (RR = 1.89, 95% CI 1.39-2.58). The insufficient suppression of viral load in patients starting with saquinavir hgc subsided during follow-up, probably owing to the earlier discontinuation of saquinavir hcg in favour of newer and more potent HAART regimens.Keywords
This publication has 10 references indexed in Scilit:
- Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV InfectionNew England Journal of Medicine, 2001
- Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavirAIDS, 2001
- Long‐Term Clinical Outcome of Human Immunodeficiency Virus–Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor–Containing RegimenThe Journal of Infectious Diseases, 2001
- Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitorAIDS, 2000
- Clinical Resistance Patterns and Responses to Two Sequential Protease Inhibitor Regimens in Saquinavir and Reverse Transcriptase Inhibitor–Experienced PersonsThe Journal of Infectious Diseases, 1999
- Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)AIDS, 1999
- Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutationsAIDS, 1999
- Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patientsAIDS, 1998
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patientsAIDS, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997